Previous 10 | Next 10 |
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arb...
Moderna (NASDAQ:MRNA) filed a motion to dismiss a lawsuit filed by two small biopharma companies seeking damages for violation of certain U.S. patents related to the company’s blockbuster COVID-19 shot, branded as Spikevax. RNA therapeutics company Genevant Sciences and clinical-stage ...
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2022 Earnings Call May 05, 2022 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q1 2022 Earnings Call Transcript
Arbutus Biopharma Corp, Inc. (ABUS) Q1 2022 Earnings Conference Call May 05, 2022, 08:45 ET Company Participants Lisa Caperelli - VP, IR William Collier - President, CEO & Director Michael Sofia - Chief Scientific Officer David Hastings - CFO & CAO Gaston Picchio - Chief Development O...
Arbutus Biopharma press release (NASDAQ:ABUS): Q1 GAAP EPS of -$0.11 beats by $0.05. Revenue of $12.58M (+496.2% Y/Y) beats by $8.16M. As of March 31, 2022, the company had cash, cash equivalents and investments in marketable securities of $221.8 million, as compared to $191.0 million as of D...
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well positioned financially with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., M...
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $4.42M (+109.5% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 down...
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled i...
Moderna projects roughly $22 billion in Spikevax sales in 2022. There are $19 billion in commitment orders in 2022 for Spikevax, and several territories with firm purchase orders established for 2023 as well. Messenger RNA technology by company being moved forward to develop possi...
Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022. An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash. ...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...